Immunosuppressive Therapies in Diabetes

Immunosuppressive therapies are being explored as potential treatments for diabetes, particularly in type 1 diabetes, where autoimmune destruction of beta cells occurs. These therapies aim to modulate the immune response, preventing further damage to insulin-producing cells. Current strategies include the use of monoclonal antibodies and low-dose chemotherapy agents to achieve immune tolerance. While promising, these therapies carry risks of infections and other complications. Research continues to identify safe and effective protocols for immunosuppression in diabetes management. Ultimately, the goal is to preserve beta-cell function and enhance metabolic control, improving the quality of life for affected individuals.